1	
2	
3	Sleep Regularity and Mortality: A Prospective Analysis in the UK Biobank
4	
5	Lachlan Cribb* (MEpi), ¹ Ramon Sha* (BSc) ¹ , Stephanie Yiallourou* (Ph.D.) ¹ , Natalie A Grima (DPsyc), ¹
6	Marina Cavuoto (Ph.D.) ^{1,2} , Andree-Ann Baril [†] (Ph.D.) ³ , Matthew P. Pase [†] (Ph.D.) ^{1,4}
7	
8	¹ Turner Institute for Brain and Mental Health, Monash University, Melbourne Australia;
9	² National Ageing Research Institute, Melbourne, Australia;
10	³ Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada;
11	⁴ Harvard T.H. Chan School of Public Health, Harvard University, MA, USA.
12	
13	*Joint first authors
14	Correspondence to: Matthew Pase, 18 Innovation Walk, Room 617, Monash University, Clayton, VIC,
15	Australia, 3800. Phone: (+61)401267924. email - matthewpase@gmail.com.
16	Word Count: 2716
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
31	
32	
33	
34	
35	
36	
37	
38	
39	

4.0	
40	ABSTRACT
41	
42	Background Irregular sleep-wake timing may cause circadian disruption leading to several chronic age-related
43	diseases. We examined the relationship between sleep regularity and risk of all-cause, cardiovascular disease
44	(CVD), and cancer mortality in 88,975 participants from the prospective UK Biobank cohort.
45	Methods The sleep regularity index (SRI) was calculated as the probability of an individual being in the same
46	state (asleep or awake) at any two time points 24 hours apart, averaged over 7-days of accelerometry (range 0-
47	100, with 100 being perfectly regular). The SRI was related to the risk of mortality in time-to-event models.
48	Findings The mean sample age was 62 years (SD, 8), 56% were women, and the median SRI was 60 (SD, 10).
49	There were 3010 deaths during a mean follow-up of 7.1 years. Following adjustments for demographic and
50	clinical variables, we identified a non-linear relationship between the SRI and all-cause mortality hazard (p
51	[global test of spline term] \leq 0.001). Hazard Ratios, relative to the median SRI, were 1.53 (95% confidence
52	interval [CI]: 1·41, 1·66) for participants with SRI at the 5 th percentile (SRI = 41) and 0·90 (95% CI: 0·81, 1·00)
53	for those with SRI at the 95 th percentile (SRI = 75), respectively. Findings for CVD mortality and cancer
54	mortality followed a similar pattern.
55	Conclusions Irregular sleep-wake patterns are associated with higher mortality risk.
56	Funding National Health and Medical Research Council of Australia (GTN2009264; GTN1158384), National
57	Institute on Aging (AG062531), Alzheimer's Association (2018-AARG-591358), and the Banting Fellowship
58	Program (#454104).
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	

2

80	INTRODUCTION		
81	Circadian rhythms are endogenous cycles in physiological, hormonal, and behavioral processes largely		
82	synchronized to the external 24-hour light-dark cycle. The sleep-wake cycle is perhaps the most notable		
83	biological process that follows the 24-hour circadian rhythm. ¹ The timing of light exposure is the primary		
84	external driver of circadian rhythms. Therefore, rapid changes in sleep timing can cause circadian misalignment		
85	through fluctuating light-dark exposure. ²		
86			
87	Circadian misalignment is associated with several age-related diseases, including cancer and cardiovascular		
88	disease (CVD). ³⁻⁵ However, the health impacts of irregular sleep wake timing are still emerging. This remains an		
89	important area of study since modern societal and lifestyle trends, including exposure to artificial and blue light		
90	at night, longer work hours, shift work, and the 24-7 lifestyle have blurred the distinction between day and		
91	night, increasing the propensity for circadian disruption. ⁶ The present study assessed the relationship between		
92	sleep regularity and the risk of incident all-cause mortality, cancer mortality, and CVD mortality in the UK		
93	Biobank (UKB). We measured sleep regularity via accelerometry to calculate the sleep regularity index (SRI), a		
94	new metric sensitive to differences in sleep-wake timing on a circadian timescale.		
95			
96	METHODS		
97	Participants		
98	Over 500,000 adults aged 40 to 69 years were recruited to the UKB cohort between 2006 and 2010 across 22		
99	assessment centers. Participants were invited by the UK National Health Service patient registers, resulting in a		
100	5.5% participation rate. Respondents were more likely to be older, female, and less likely to live in		
101	socioeconomically deprived areas than the general population.' Baseline demographics, medical history,		
102	lifestyle, vitals, and blood samples were collected. A total of 106,053 participants completed a 7-day wrist-worn		
103	accelerometer study through random selection between February 2013 and December 2015.		
104	Magnument of door non-larity		
105	Accelerement of steep regularity		
100	day/night period. Estimated sleep status (awake or asleep) at a given time was calculated using the open source.		
107	P package GCIP version 2:7.1. ⁸ using available algorithms ^{9,10} Accelerometry data of low guality were		
100	removed using established UKB criteria (Appendix 1, pg. 3). In total, 88,975 (84%) participants provided valid		
110	SRI data and were included in the study.		
111			
112	The SRI captures the probability of a participant being in the same state (asleep or awake) at any two time		
113	points 24 hours apart. ¹¹ An individual who sleeps and wakes at precisely the same time each day would have an		
114	index of 100, whereas an individual who sleeps and wakes at entirely random times would have an index of 0.		
115	Each participant provided k -1 SRI measurements (where k is the number of valid 24-hour periods), one for each		
116	contiguous two-day pair. These SRI measurements were averaged using a linear mixed effects model with a		
117	random intercept for the participant and fixed effects for the day of the week and daylight savings transition. The		
118	average SRI was standardized over the day of the week and daylight savings transitions, so all SRI results were		

119 comparable.

3

120 121 Mortality ascertainment 122 Mortality occurrence was identified through linkage with NHS Digital for participants from England and Wales 123 and the NHS Central Register for participants from Scotland, with complete records available until January 124 2022. Death records included the date of death and the ICD-10 code for the primary cause. ICD-10 codes 100-125 199 and C00-C97 defined CVD and cancer mortality, respectively. 126 127 Ascertainment of prevalent disease at baseline 128 Prevalent cancer (ICD-10 codes D00-D09 and D37-D48), diabetes (codes E10-E14), mental and behavioral 129 disorders (codes F00-F99), nervous system disorders (codes G00-G99), and CVD (codes I00-I99) at the time of 130 the accelerometry study were ascertained through self-report at the UKB baseline session and through linkage 131 with hospital inpatient records using the above ICD-10 codes. Linkage with hospital inpatient records was also 132 used to identify disease occurrence between the UKB baseline session and the time of the accelerometry study. 133 134 Data Analysis 135 Data analysis was performed using R version $4 \cdot 2 \cdot 1$. Cox proportional hazards models were used to examine 136 associations between the SRI and incident all-cause mortality, CVD mortality, and cancer mortality. 137 Surveillance for mortality commenced from the time of accelerometry (2013-2015) until the end of follow-up 138 (January 2022), with a median follow-up time of 7.1 years (Q1, Q3: 6.6, 7.6). Non-events were censored at the 139 last date they were known to be alive. For CVD and cancer mortality, deaths from competing causes were 140 censored at the time of death. The SRI and all continuous confounders were modeled with restricted cubic 141 splines with knots at the 10th, 50th, and 90th percentiles to allow for departures from linearity. Missing data 142 were infrequent (< 2%) for most confounder variables and were imputed (10 imputations) by predictive mean 143 matching using the aregImpute function of R package Hmisc.¹² 144 145 In addition to Cox models, discrete-time hazards models, including an interaction between SRI and time (aggregated into 3-month intervals and modeled with a restricted cubic spline with knots at the 5th, 35th, 65th, and 146 147 95th percentiles), were fitted to determine whether Hazard Ratios (HRs) varied over time.¹³ Time-varying HRs 148 were then displayed visually. In cases where HRs showed clear time-variation (i.e., hazards were non-149 proportional), we nonetheless present HRs from the Cox models as these can be interpreted as a weighted 150 average of the time-varying HRs.¹⁴ The discrete-time hazards model for all-cause mortality was also used to 151 estimate standardized cumulative incidence (risk) across levels of SRI, with confidence intervals obtained by 152 bootstrapping.¹⁵ To reduce computation demand, only single imputation was used for the discrete-time hazards 153 models. 154 155 All models were adjusted for the following variables that were selected using a directed acyclic graph

156 (Appendix, Figure S1): age, sex, ethnicity (White, Asian, mixed race, Black, or other), Townsend deprivation

- 157 index, retirement status (retired vs. all other work arrangements), shift work (shift worker vs. non-shift worker),
- 158 sick or disabled (self-reported employment category), household income (ordinal with 5 levels), highest level of

4

education (ordinal with 6 levels), smoking status (current, former, never), smoking (pack years), and use of sedative, antidepressant, or antipsychotic medication.

161

162 Sensitivity analyses

163 We fitted a second statistical model to determine whether the observed associations were independent of sleep 164 time and disruption. Therefore, Model 2 included additional adjustments for overnight sleep duration and wake 165 after sleep onset (WASO), averaged across accelerometry days (plus primary model covariates). In the second 166 sensitivity analysis (Model 3), we adjusted for prevalent disease at baseline (cancer, CVD, mental and 167 behavioural disorders, nervous system disorders, diabetes), in addition to the variables in the primary model. 168 These variables were included as part of a sensitivity analysis as it is unclear whether they may be mediators or 169 confounders of the SRI-mortality relationship. Long-standing irregular sleep may lead to prevalent disease at 170 baseline and influence disease risk factors.¹⁶⁻¹⁹ indicating that prevalent disease variables may play a mediating 171 role (and consequently should not be adjusted). Conversely, prevalent disease may have effects disruptive to 172 regular sleep and these variables may therefore confound the SRI-mortality relationship. Disease risk factor 173 variables body mass index (BMI), moderate and vigorous physical activity (accelerometry-derived), systolic 174 blood pressure (BP), and use of BP lowering medication, in addition to the variables in Model 3, were included 175 in a final sensitivity analysis (Model 4), as it is similarly unclear whether they may confound or mediate the 176 SRI-mortality relationship. 177 178 *Comparison of SRI with other regularity measures*

179 Preliminary reports which identified irregular sleep as a potential CVD risk factor measured sleep regularity as 180 the amount of deviation in sleep patterns from an individual's average (i.e., the standard deviation [SD] of nocturnal sleep duration and sleep onset time).^{20,21} To contrast these SD-based metrics with the SRI, we fitted 181 182 independent Cox models (each with primary model covariates) and estimated HRs for all-cause mortality for 183 each of the three measures. Additionally, we added the SRI to a model containing both SD-based regularity 184 measures (alongside primary model covariates) to test whether the SRI contained additional mortality risk 185 information beyond that captured by the two SD metrics. 186 187

188

RESULTS

189**Table 1** displays sample characteristics. The final sample size was 88,975. There were 3010 all cause deaths190during a median follow-up of $7 \cdot 1$ years (Q1, Q3: $6 \cdot 6, 7 \cdot 6$). The most common primary cause of death was191cancer (n = 1701, 57%) followed by CVD (n = 616, 20%).

192

193 SRI and all-cause mortality

194 We identified a non-linear association between the SRI and all-cause mortality hazard (*p* [global test of spline

term] < 0.001) (Figure 1). Compared to the sample median (SRI = 61), mortality rates were highest among

196 those with the most irregular sleep and decreased almost linearly as SRI approached its median, after which the

decrease began to plateau (Figure 1). HRs, relative to the median SRI, were 1.53 (95% CI: 1.41, 1.66) for

198 participants with SRI at the 5th percentile (SRI = 41) and 0.90 (95% CI: 0.81, 1.00) for those with SRI at the 95th

- 200 displayed for the SRI at the 5th percentile, median, and 95th percentile in **Figure 2**.
- 201

202 There was evidence of non-proportionality of hazards across levels of SRI in the discrete-time hazards model (p

203 [time x SRI interaction] < 0.001). Time-varying HRs for the 5th and 95th SRI percentiles compared to the median

are displayed in the appendix (Figure S2). For the 5th percentile relative to the median, HRs were greatest in the

205 earliest period of follow-up (HRs> 2), declining until approximately 2.5 years, after which they remained

- approximately stable with a HR of around 1.5. There was no clear time variation in the HR for the 95th
- 207 percentile of SRI vs. the median.
- 208

209 CVD-specific mortality

- 210 The SRI was associated with CVD-specific mortality in the primary model (p [global] < 0.001; Figure 1). HRs,
- 211 relative to the median SRI, were 1.88 (95% CI: 1.61, 2.21) and 0.93 (95% CI: 0.73, 1.20) for the 5th and 95th
- 212 percentiles, respectively. There was no evidence of non-proportional hazards in the discrete-time hazards model
- 213 (*p* [time x SRI interaction] = 0.57).
- 214

215 *Cancer-specific mortality*

- 216 The SRI was associated with cancer mortality in the primary model (p [global] < 0.001). HRs, relative to the
- 217 median SRI, were 1.36 (95% CI: 1.22, 1.53) and 0.89 (95% CI: 0.77, 1.02) for the 5th and 95th percentiles,
- 218 respectively. There was strong evidence of non-proportional hazards in the cancer-mortality discrete-time
- 219 hazards model (p [time x SRI interaction] < 0.001). HRs, for the 5th percentile vs. the median, were large at the
- 220 beginning of follow-up (HRs> 2) and declined until approximately four years, after which they were small (~
- 1.05) and compatible with the null (Appendix, Figure S3). There was no indication that HRs for the 95th SRI
- 222 percentile relative to the median varied over follow-up.
- 223
- 224 Sensitivity analyses
- 225 Sensitivity analyses are displayed in the appendix (Figures S4-6). Overall, results were similar and not
- 226 meaningfully altered following adjustments for sleep time and WASO (Model 2) or prevalent baseline disease,
- 227 including cancer and CVD (Model 3). The SRI remained associated with mortality after further adjustments for
- 228 prevalent diseases, BMI, systolic BP, BP treatment, and physical activity (Model 4), though effect sizes were
- attenuated. For example, when comparing the 5^{th} percentile to the median, HRs were 1.22 (95% CI: 1.07, 1.39)
- 230 for all-cause, 1.43 (95% CI: 1.21, 1.69) for CVD, and 1.15 (95% CI: 1.01, 1.29) for cancer mortality.
- 231

232 Comparison of SRI with sleep duration SD and sleep onset time SD

- 233 Figure 3 displays HRs, relative to the median, for the SRI, sleep duration SD, and sleep onset time SD. For each
- 234 measure, greater sleep irregularity (i.e., lower SRI or higher SD representing more day-to-day variability) was
- associated with an increased all-cause mortality rate in independent models (all p [global] < 0.001). HRs, for
- 236 low regularity compared to the median, were largest for the SRI (Figure 3). The addition of the SRI to a model
- 237 containing both SD metrics (alongside primary model covariates) improved model fit (p [likelihood ratio test] <

238	0.001). Conversely, the addition of sleep duration SD and sleep onset time SD to a model containing the SRI		
239	(and primary model covariates) did not meaningfully improve model fit (p [likelihood ratio test] = 0.10).		
240			
241			
242	DISCUSSION		
243	Among 88,975 individuals followed for a median of 7.1 years, there was a non-linear association between sleep		
244	regularity and the risk of mortality; mortality rates were highest in persons with the most irregular sleep and		
245	decreased approximately linearly as sleep regularity approached its median, after which the decrease began to		
246	plateau. Our findings were independent of prevalent illness (including cancer and CVD at baseline), sleep		
247	duration, sleep fragmentation, and other confounding factors. Overall, these data indicate a relationship between		
248	sleep regularity and longevity in a large community-based cohort.		
249			
250	Physiological processes associated with CVD and cancer are under circadian control. Mutations or deletions to		
251	circadian clock genes such as CLOCK, PER, and BMAL1 influence BP, endothelial function, and glucose		
252	homeostasis. ²²⁻²⁵ Both major (e.g., chronic shift work) and minor (e.g., daylight savings transitions) stressors to		
253	the circadian system have been associated with a higher risk of CVD. ^{3,5} Similarly, circadian misalignment has		
254	also been implicated in the pathogenesis of cancer. For example, circadian clocks are critical to the orchestration		
255	of cell division ²⁶ , and altered clock function can precipitate aberrant cell proliferation ²⁷ as well as growth and		
256	DNA damage in cancer cells. ²⁸ Many systems are under circadian influence, including the sleep-wake cycle, and		
257	less clear has been the extent to which differences in sleep regularity are related to negative health outcomes. We		
258	extend this research by demonstrating that differences in sleep regularity are associated with the risk of mortality		
259	from both CVD and cancer.		
260			
261	Whereas sleep regularity has not been examined with respect to incident cancer or mortality, the current findings		
262	extend research showing that greater sleep-wake variability, as measured by the SD of sleep onset or duration,		
263	was independently associated with a higher risk of incident CVD in the multi-ethnic study of atherosclerosis but		
264	not the UK Biobank. ^{20,21} We demonstrate that the SRI contains information about mortality risk beyond that		
265	contained in the SD of sleep duration and onset, whereas the converse was not the case. The SRI may be		
266	superior to the SD-based metrics because the SRI captures rapid changes in sleep patterns across consecutive		
267	days, as compared to the SD-based metrics which only calculate deviation from an individual's average. Rapid		
268	changes in sleep timing have been hypothesised as being principally challenging for the circadian system to		
269	accommodate ¹¹ which may, in turn, produce negative health outcomes.		
270			
271	We found evidence that hazard rates across levels of SRI were non-proportional (i.e., varied across the follow-		
272	up period) for all-cause and cancer mortality (which accounted for most deaths), though not for CVD mortality.		
273	For cancer mortality, HRs for low SRI compared to the median were largest in the earliest follow-up period and		
274	decreased thereafter. One plausible interpretation of this finding is that irregular sleep may be a manifestation of		
275	the underlying physiological processes of cancer itself or of cancer treatment (i.e., the SRI-cancer mortality		
276	association may be due to reverse causation). However, this thesis is challenged by the fact that associations		
277	between the SRI and cancer mortality remained similar after adjusting for prevalent cancer at baseline. In the		

7

278	case of CVD mortality, no such evidence of a decline in HRs over follow-up time was evident; a potential causal
279	role of irregular sleep on CVD death cannot be easily ruled out.
280	
281	Sleep of insufficient or excessive duration is associated with many adverse health outcomes, including increased
282	mortality risk. ²⁹ As of 2022, sleep duration was included by the American Heart Association in their Essential
283	Eight guidelines for CVD prevention. ³⁰ However, sleep is far more complex than its habitual duration and
284	quality, with sleep regularity receiving comparatively little attention. As sleep-tracking wearables become more
285	accessible, objective measurement of sleep regularity has the potential for public and clinical use. Much like
286	sleep duration, replicating the current findings across different samples will be necessary for establishing
287	population norms and clinical targets.
288	
289	Our study is not without limitations. Firstly, the study was observational. We are, therefore, unable to establish
290	cause and effect. Although we performed extensive analyses to control for confounding, we cannot exclude the
291	possibility that our results are explained by residual confounding. As such, although therapies exist for
292	improving sleep regularity, it's not clear if these interventions are able to extend the lifespan. Second, sleep and
293	wake were estimated through activity patterns from accelerometry. As compared to polysomnography, there is
294	the potential to misclassify sleep and wake, although accelerometry is more suited to estimate circadian patterns
295	over several days; there are several strengths to using accelerometry (e.g., days of continuous recording,
296	minimal technical apparatus affecting sleep quality), making it the recommended clinical tool for assessing
297	circadian rhythms. ³¹
298	
299	Circadian rhythms have a major influence on health and disease. Although sleep wake timing is under circadian
300	control, research on sleep regularity as a risk factor for mortality was equivocal. These data suggest sleep
301	regularity as an important correlate of longevity, independent of sleep duration, fragmentation, and quality.
302	Future work is needed to determine the underlying mechanisms to inform possible interventions to extend the
303	lifespan.
304	
305	FUNDING
306	Dr. Pase is supported by a National Health and Medical Research Council of Australia Investigator Grant
307	(GTN2009264) with sleep research funding from the National Health and Medical Research Council of
308	Australia (GTN1158384), National Institute on Aging (R01 AG062531) and Alzheimer's Association (2018-
309	AARG-591358). Dr. Baril is funded by the Banting Fellowship Program (#454104). The funders of the study
310	had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
311	
312	
313	ACKNOWLEDGMENTS
314	This research has been conducted using the UK Biobank Resource.
315	
316	DATA SHARING

317 Data from the UK Biobank are available, pending application approval from: https://www.ukbiobank.ac.uk/

318	REFERENCES
319	1. Zee PC, Vitiello MV. Circadian Rhythm Sleep Disorder: Irregular Sleep Wake
320	Rhythm Type. <i>Sleep Med Clin</i> 2009; 4 (2): 213-8.
321	2. Zeitzer JM, Dijk DJ, Kronauer R, Brown E, Czeisler C. Sensitivity of the human
322	circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol
323	2000; 526 Pt 3 (Pt 3): 695-702.
324	3. Torquati L, Mielke GI, Brown WJ, Kolbe-Alexander T. Shift work and the risk of
325	cardiovascular disease. A systematic review and meta-analysis including dose-response
326	relationship. Scand J Work Environ Health 2018; 44(3): 229-38.
327	4. International-Agency-for-Research-on-Cancer. Painting, firefighting, and shiftwork.
328	IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2010; 98: 804.
329	5. Janszky I, Ljung R. Shifts to and from Daylight Saving Time and Incidence of
330	Myocardial Infarction. New England Journal of Medicine 2008; 359 (18): 1966-8.
331	6. Walker WH, Walton JC, DeVries AC, Nelson RJ. Circadian rhythm disruption and
332	mental health. Translational Psychiatry 2020; 10(1): 28.
333	7. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-
334	Related Characteristics of UK Biobank Participants With Those of the General Population.
335	<i>Am J Epidemiol</i> 2017; 186 (9): 1026-34.
336	8. Migueles JH, Rowlands AV, Huber F, Sabia S, van Hees VT. GGIR: a research
337	community-driven open source R package for generating physical activity and sleep
338	outcomes from multi-day raw accelerometer data. Journal for the Measurement of Physical
339	<i>Behaviour</i> 2019; 2 (3): 188-96.
340	9. Van Hees VT, Sabia S, Anderson KN, et al. A novel, open access method to assess
341	sleep duration using a wrist-worn accelerometer. <i>PloS one</i> 2015; 10 (11): e0142533.
342	10. van Hees VT, Sabia S, Jones SE, et al. Estimating sleep parameters using an
343	accelerometer without sleep diary. <i>Scientific reports</i> 2018; 8 (1): 1-11.
344	11. Phillips AJ, Clerx WM, O'Brien CS, et al. Irregular sleep/wake patterns are associated
345	with poorer academic performance and delayed circadian and sleep/wake timing. Scientific r_{1} and r_{2} and r_{2} and r_{3} and r_{4} and
340 247	<i>reports 2017; 7(1): 1-13.</i>
247 249	12. Finder ID Willett ID Applied Longitudinal Data Applysics Modeling Change and
240 240	Fyont Occurrence: Oxford University Press: 2002
349	14 Stensrud MI Hernán MA Why Test for Proportional Hazards? IAMA 2020: 373 (14):
350	14. Stensidd MJ, Hernan MA. Why fest for i toportional frazards? <i>JAMA</i> 2020, $323(14)$.
357	15 Hernán MA Robins IM Causal inference CRC Roca Raton EL: 2010
352	16 Fritz I Phillips A IK Hunt L et al Cross-sectional and prospective associations
354	between sleep regularity and metabolic health in the Hispanic community Health Study/Study
355	of Latinos Sleen 2021: 44(4): 75aa218
356	17 Huang T Redline S. Cross-sectional and prospective associations of actigraphy-
357	assessed sleep regularity with metabolic abnormalities: the multi-ethnic study of
358	atherosclerosis. <i>Diabetes care</i> 2019: 42 (8): 1422-9.
359	18. Huang W-C. Chang S-H. Hsueh M-C. Liao Y. Relationship of sleep regularity with
360	device-based sedentary behavior time and physical activity time in working adults. <i>Sleep</i>
361	Health 2022.
362	19. Zuraikat FM, Makarem N, Redline S, Aggarwal B, Jelic S, St-Onge M-P. Sleep
363	regularity and cardiometabolic heath: is variability in sleep patterns a risk factor for excess
364	adiposity and glycemic dysregulation? Current diabetes reports 2020; 20(8): 1-9.
365	20. Nikbakhtian S, Reed AB, Obika BD, et al. Accelerometer-derived sleep onset timing
366	and cardiovascular disease incidence: a UK Biobank cohort study. European Heart Journal -
367	<i>Digital Health</i> 2021; 2 (4): 658-66.

368	21. Huang T, Mariani S, Redline S. Sleep Irregularity and Risk of Cardiovascular Events:		
369	The Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 2020; 75(9): 991-9.		
3/0	22. Viswambharan H, Carvas JM, Antic V, et al. Mutation of the Circadian Clock Gene		
3/1	<1>Per2 $> Alters vascular Endotnelial Function. Circulation 2007; 115(16): 2188-95.$		
372	23. Curtis AM, Cheng Y, Kapoor S, Keilly D, Price TS, Fitzgerald GA. Circadian		
3/3	Variation of blood pressure and the vascular response to asynchronous stress. <i>Proc Natl Acaa</i>		
275	Sci U S A 2007, 104(9). 5450-5.		
375	circodion clock. Circulation 2000: 110 (11): 1510.7		
370	25 Pudic PD McNamara D Curtis AM at al BMAI 1 and CLOCK two assential		
378	components of the circadian clock are involved in glucose homeostasis. PLoS Riol 2004:		
370	$2(11) \cdot e^{377}$		
380	26 Reddy AB Wong GK O'Neill I Maywood FS Hastings MH Circadian clocks:		
381	neural and peripheral pacemakers that impact upon the cell division cycle <i>Mutat Res</i> 2005:		
382	574 (1-2): 76-91		
383	27. Wang O, Ao Y, Yang K, Tang H, Chen D. Circadian clock gene Per2 plays an		
384	important role in cell proliferation, apoptosis and cell cycle progression in human oral		
385	squamous cell carcinoma. Oncol Rep 2016; 35 (6): 3387-94.		
386	28. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per l		
387	plays an important role in cell growth and DNA damage control in human cancer cells. <i>Mol</i>		
388	<i>Cell</i> 2006; 22 (3): 375-82.		
389	29. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause		
390	mortality: a systematic review and meta-analysis of prospective studies. Sleep 2010; 33(5):		
391	585-92.		
392	30. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and		
393	Enhancing the American Heart Association's Construct of Cardiovascular Health: A		
394	Presidential Advisory From the American Heart Association. <i>Circulation</i> 2022; 146 (5): e18-		
395	e43.		
396	31. Smith MT, McCrae CS, Cheung J, et al. Use of Actigraphy for the Evaluation of Sleep		
397	Disorders and Circadian Rhythm Sleep-Wake Disorders: An American Academy of Sleep		
398	Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. J Clin Sleep Med		
399	2018; 14(7): 1209-30.		
400			
401			
402			
403			
404			
405			

1	Λ
	()
т	υ

407	Table 1: Sample characteristics $(n - 88.075)$
407	Variable

Variable	Summary
Sex (male), n (%)	38,868 (44)
Age (years)	61.9 (7.8)
BMI	26.7 (4.5)
Ethnicity, n (%)	
Asian	3,423 (4)
Black	342 (0.4)
Mixed race	2,513 (3)
White	81,902 (92)
Other	507 (1)
Townsend deprivation index (score units), median (Q1-Q3)	-2.44 (-3.81, -0.17)
Household income* (thousands), n (%)	
<18	11,784 (15)
18-30	19,340 (24)
31-50	22,936 (29)
51-100	19,984 (25)
>100	5,786 (7)
Retired, n (%)	27,893 (31)
Shift worker, n (%)	3,927 (4)
Smoking status, n (%)	
Current	6,104 (7)
Former	31,910 (36)
Never	50,718 (57)
Sedative medication, n (%)	781 (<1)
Antidepressant medication, n (%)	5,145 (6)
Prevalent cancer, n (%)	11,638 (13)
Prevalent CVD, n (%)	36,279 (41)
Prevalent diabetes, n (%)	3,759 (4)
Prevalent neurological disease, n (%)	10,793 (12)
Prevalent mental and behavioural disorder, n (%)	8,187 (9)
Average night time sleep duration (hours; actigraphy-derived)	6.57 (8.33)
Average night time wake after sleep onset (hours; actigraphy-derived)	0.79 (0.27)
Sleep duration SD, hours	1.13 (0.57)
Sleep onset time SD, hours	1.02 (0.85)
SRI, score units	60.1 (10.2)

408 Data are mean (SD), unless specified otherwise. *pounds. SRI = sleep regularity index; CVD = cardiovascular

409 disease.

410



412

413 Figure 1. Adjusted hazard ratios for all-cause (A), CVD (B), and cancer (C) mortality.

414 *P* values from global (2 degree of freedom) test of spline term. Hazard ratios (HR) are relative to the median

415 SRI (SRI = 60). HRs for all-cause mortality, CVD mortality, and cancer mortality were estimated using Cox

416 proportional hazards models, adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic,

417 and sedative medication, ethnicity, household income, education, smoking status (former, current, never),

418 smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category). All

419 continuous confounders and the SRI were modeled with restricted cubic splines (knots at 10th, 50th, and 90th

420 percentiles) to allow for departures from linearity.

421



423

424 Figure 2. Cumulative incidence of all-cause mortality across SRI.

425 Standardized cumulative incidence of all-cause mortality for SRI at 41 (5th percentile), 61 (median), and 75 (95th

426 percentile). Estimates from a discrete-time hazards models including an interaction between SRI and time

- 427 (aggregated into 3-month intervals and modeled with a restricted cubic spline with knots at the 5th, 35th, 65th, and
- 428 95th percentiles) and primary model covariates. Confidence intervals were obtained by bootstrapping.
- 429
- 430



431

Figure 3. Adjusted hazard ratios for all-cause mortality for the SRI (A), sleep duration SD (B), and sleep
onset SD (C) measures.

434 *P* values from global (2 degree of freedom) test of exposure spline term. Hazard ratios (HR) are relative to the

435 median SRI (SRI = 60). HRs were estimated using Cox proportional hazards models, adjusted for age,

436 Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household

437 income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status,

438 and sick or disabled (self-reported employment category). All continuous confounders and the sleep regularity

- 439 metrics were modeled with restricted cubic splines (knots at 10th, 50th, and 90th percentiles) to allow for
- 440 departures from linearity.

441 Supplementary appendix

442	Supplement to: Cribb, Sha, Yiallourou, et al. Sleep Regularity and Mortality: A Prospective Analysis in the UK
443	Biobank
444	
445	
446	
447	
448	
449	
450	
451	
452	
453	
454	
455	
456	
457	
458	
459	
460	
461	
462	
463	
464	
465	
466	
467	
468	
469	
470	
471	
472	
473	
474	
475	
476	

477	Appendix						
478	Table of Contents						
479	Appendix 1: Removal of low-quality accelerometer data						
480	Appendix 2: STROBE checklist						
481	Figure S1. Directed acyclic graph for identification of adjustment variables						
482	Figure S2. Time-varying HRs for 5 th and 95 th percentiles of SRI (relative to median) for all-cause mortality						
483	Figure S3. Time-varying HRs for 5 th and 95 th percentiles of SRI (relative to median) for cancer-mortality						
484	Figure S4. SRI and all-cause mortality in sensitivity analyses						
485	Figure S5. SRI and CVD-mortality in sensitivity analyses						
486	Figure S6. SRI and cancer-mortality in sensitivity analyses						
487							
488							
489							
490							
491							
492							
493							
494							
495							
496							
497							
498							
499							
500							
501							
502							
503							
504							
505							
506							
507							
508							
509							
510							
511							
512							
513							
514							
515							
516							

517 Appendix 1: Methods. Removal of low-quality accelerometer data

- 518 519 Accelerometry data of low quality were removed using established UKB criteria;
- incongruity of self-reported wear time and accelerometer wear time data (5%); insufficient wear time (<72
- 520 hours; 5%); and poorly calibrated data (<1%). Lastly, data were removed for participants in which GGIR was
- unable to determine a sleep window (5%) and for participants providing less than two valid SRI measurements
- 521 522 (i.e., 2 24-hour wear periods; <1%). In total, 88,975 (84%) participants provided valid sleep regularity index
- 523 data and were included in the study.
- 524

4

	Item No	Percommondation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found (see pg 2)
		done and what was found (see pg 2)
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported (pg 3)
Objectives	3	State specific objectives, including any prespecified hypotheses (pg 3)
Methods		
Study design	4	Present key elements of study design early in the paper (Pg 3)
Setting	5	Describe the setting, locations, and relevant dates, including periods of rearritment exposure follow up and date collection (Pg 3)
Douticipanta	6	(a) Cive the eligibility eviterie and the sources and methods of selection of
Participants	0	(a) Give the englotinty criteria, and the sources and methods of selection of participants. Describe methods of follow up ($Pg(3,4)$)
		(b) For matched studies, give matching criteria and number of exposed and
		unexposed NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and
	,	effect modifiers. Give diagnostic criteria, if applicable (Pg 4)
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement	-	assessment (measurement). Describe comparability of assessment methods it
		there is more than one group (Pg 3-4)
Bias	9	Describe any efforts to address potential sources of bias (pg 5)
Study size	10	Explain how the study size was arrived at (pg 3 and appendix)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If
		applicable, describe which groupings were chosen and why (pg 5)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for
		confounding (pg 4-5, Figure S1)
		(b) Describe any methods used to examine subgroups and interactions NA
		(c) Explain how missing data were addressed (pg 4-5)
		(d) If applicable, explain how loss to follow-up was addressed
		(e) Describe any sensitivity analyses (pg 5)
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers
1		potentially eligible, examined for eligibility, confirmed eligible, included in
		the study, completing follow-up, and analysed (Pg 3)
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram Not considered necessary but can be
		created upon request
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,
		social) and information on exposures and potential confounders Table 1
		(b) Indicate number of participants with missing data for each variable of
		interest
		Missing data were infrequent, as described in methods
		(c) Summarise follow-up time (eg, average and total amount) (pg 5)
Outcome data	15*	Report numbers of outcome events or summary measures over time (pg 5)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted
		estimates and their precision (eg, 95% confidence interval). Make clear whic
		confounders were adjusted for and why they were included Figures and
		Appendix figures
		(b) Report category boundaries when continuous variables were categorized
		NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk
		for a meaningful time period Figure 2

525 Appendix 2: STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

4	L	
		۰.
		,
		2

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses (pg 6)
Discussion		
Key results	18	Summarise key results with reference to study objectives (pg 7)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias (pg 8)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence (pg 8)
Generalisability	21	Discuss the generalisability (external validity) of the study results (pg 7-8)
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based $(pg 8)$

527 *Give information separately for exposed and unexposed groups.

529 Note: An Explanation and Elaboration article discusses each checklist item and gives methodological

530 background and published examples of transparent reporting. The STROBE checklist is best used in conjunction

531 with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of

532 Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the

533 STROBE Initiative is available at http://www.strobe-statement.org.534







553 Figure S1. Directed acyclic graph for identification of adjustment variables. The green node indicates the 554 exposure variable (SRI), and the blue node (Mortality) is the outcome variable. Pale grey nodes indicate 555 556 557 unobserved variables; white nodes indicate a variable which has been conditioned on (by regression adjustment or restriction). Paths in red are biasing paths. Arrows indicate the direction of causal effect between two nodes. P is an unobserved variable representing unmeasured causes of sleep habits (e.g., genetics). U is an unobserved 558 variable representing unmeasured causes of disease and cardiovascular dysfunction (e.g., genetics, biological 559 ageing). Z is an unobserved variable representing unmeasured causes of health behaviours (e.g., personality 560 factors, genetics). Green paths from SRI to Prevalent disease, BP medication, Systolic BP, BMI, and Physical 561 activity and from these nodes to Mortality represent potential mediation of an SRI effect. Conversely, red paths 562 indicate potential sources of confounding (e.g., a backdoor path from Mortality to Prevalent disease to SRI via 563 U). Given the current evidence base, we are unable to determine whether and to what extent variables such as 564 Prevalent disease act as mediators or confounders (via U) of the SRI-mortality association. AP = anti-psychotic; 565 AD = antidepressant; BMI = body mass index; BP = blood pressure; CVD = cardiovascular disease; Deprivation 566 = the Townsend deprivation index; SRI = sleep regularity index; WASO = wake after sleep onset.





Figure S2. Time-varying HRs for 5th and 95th percentiles of SRI (relative to median) for all-cause

mortality. A: Hazard ratios for 5th percentile vs median SRI; B: Hazard ratios for 95th percentile vs median SRI. Discrete time hazards model including time (aggregated into 3-month intervals and modelled with a restricted cubic spline with knots at the 5th, 35th, 65th, and 95th percentiles), SRI, and an SRI by time interaction. Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category). All continuous confounders and the SRI were modelled with restricted cubic splines (knots at 10th, 50th, and 90th percentiles) to allow for departures from linearity. There was strong evidence of an interaction between time and SRI (p [interaction] < 0.001).

- 579
- 581





Figure S3. Time-varying HRs for 5th and 95th percentiles of SRI (relative to median) for cancer-mortality. A: Hazard ratios for 5th percentile vs median SRI; **B:** Hazard ratios for 95th percentile vs median SRI. Discrete time hazards model including time (aggregated into 3-month intervals and modelled with a restricted cubic spline with knots at the 5th, 35th, 65th, and 95th percentiles), SRI, and an SRI by time interaction. Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category). All continuous confounders and the SRI were modelled with restricted cubic splines (knots at 10th, 50th, and 90th percentiles) to allow for departures from linearity. There was strong evidence of an interaction between time and SRI (p [interaction] < 0.001).

9



610 611 612

612 Figure S4. SRI and all-cause mortality in sensitivity analyses. *P* values from global (2 degree of freedom)
613 test of spline term. Hazard ratios are relative to the median SRI (SRI = 60).
614

Model 2 (M2) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant,
antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current,
never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment
category), average sleep time, and average wake after sleep onset time. M2 results: HRs, relative to the median
SRI, were 1.42 (95% CI: 1.31, 1.55) and 0.90 (95% CI: 0.80, 1.00) for SRI at the 5th and 95th percentiles,
respectively.

Model 3 (M3) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant,
antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current,
never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment
category), and prevalent diabetes, cancer, mental and behavioural disorder, neurological illness, and
cardiovascular illness. M3 Results: HRs, relative to the median SRI, were 1.46 (95% CI: 1.35, 1.58) and 0.93
(95% CI: 0.83, 1.03) for the 5th and 95th percentiles of SRI, respectively.

626 (95% CI: 0.83, 1.03) for the 5th and 95th percentiles of SRI, respectively.
627 Model 4 (M4) adjustments: Model 3 with additional adjustment for BMI, moderate and vigorous
628 physical activity, systolic blood pressure, and blood pressure medication. M4 results: HRs, relative to the
629 median SRI, were 1.20 (95% CI: 1.11, 1.31) and 1.00 (95% CI: 0.90, 1.12) for the 5th and 95th percentiles,
630 respectively.

10





Figure S5. SRI and CVD-mortality in sensitivity analyses. *P* values from global (2 degree of freedom) test of
 spline term. Hazard ratios are relative to the median SRI (SRI = 60).

Model 2 (M2) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant,
antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current,
never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment
category), average sleep time, and average wake after sleep onset time. M2 results: HRs were 1.66 (95% CI:
1.40, 1.96) and 0.95 (95% CI: 0.73, 1.22) for the 5th and 95th percentile vs. the median SRI, respectively.

Model (M3) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant,
antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current,
never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment
category), and prevalent diabetes, cancer, mental and behavioural disorder, neurological illness, and
cardiovascular illness. M3 results: HRs were 1.73 (95% CI: 1.47, 2.02) and 0.99 (95% CI: 0.77, 1.26) for the 5th
and 95th percentiles, respectively.

Model 4 (M4) adjustments: Model 3 with additional adjustment for BMI, moderate and vigorous
physical activity, systolic blood pressure, and blood pressure medication. M4 results: HRs were somewhat
attenuated: 1.43 (95% CI: 1.21, 1.69) and 1.09 (95% CI: 0.85, 1.40), for the 5th and 95th percentiles, respectively.

11



652

Figure S6. SRI and cancer-mortality in sensitivity analyses. *P* values from global (2 degree of freedom) test of spline term. Hazard ratios are relative to the median SRI (SRI = 60).

Model 2 (M2) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant,
antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current,
never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment
category), average sleep time, and average wake after sleep onset time. M2 results: HRs were 1.35 (95% CI:
1.20, 1.52) and 0.88 (95% CI: 0.76, 1.02) for the 5th and 95th percentile vs. the median SRI, respectively.

660 Model 3 (M3) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant, 661 antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, 662 never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment 663 category), and prevalent diabetes, cancer, mental and behavioural disorder, neurological illness, and 664 cardiovascular illness. M3 results: HRs were 1.33 (95% CI: 1.19, 1.49) and 0.90 (95% CI: 0.78, 1.04) for the 5th 665 and 95th percentiles, respectively.

Model 4 (M4) adjustments: Model 3 with additional adjustment for BMI, moderate and vigorous
physical activity, systolic blood pressure, and blood pressure medication. M4 results: HRs were 1.15 (95% CI: 1.02, 1.30) and 0.97 (95% CI: 0.84, 1.12) for the 5th and 95th percentiles, respectively.

- 669
- 670
- 671